NING LI1,#, YANG CHEN2,#, YONGJIE YANG3,4, SHUHAN LYU1, YUE PAN1,5,*
BIOCELL, Vol.46, No.6, pp. 1473-1482, 2022, DOI:10.32604/biocell.2022.018278
- 07 February 2022
Abstract Breast cancer is a highly aggressive cancer in females. Metastasis is a major obstacle to the efficient and successful treatment of breast cancer. Cetyltrimethylammonium bromide (CTAB) has anti-tumor effects on a variety of tumors. We showed that CTAB inhibits the metastasis of breast cancer to the lungs both in vitro and in vivo. Epithelial-mesenchymal transition (EMT) is thought to be one of the major processes mediating breast cancer metastasis. We found that CTAB suppressed EMT and regulated the levels of the classical EMT markers E-cadherin, N-cadherin, vimentin, Snail and Twist1. Moreover, as a candidate anti-tumor agent, CTAB More >
Login
Register
